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Sharing of experimental clinical research data usually happens between individuals or research groups rather than
via public repositories, in part due to the need to protect research participant privacy. This approach to data
sharing makes it difficult to connect journal articles with their underlying datasets and is often insufficient for
ensuring access to data in the long term. Voluntary data sharing services such as the Yale Open Data Access
(YODA) and Clinical Study Data Request (CSDR) projects have increased accessibility to clinical datasets for secondary
uses while protecting patient privacy and the legitimacy of secondary analyses but these resources are generally
disconnected from journal articles—where researchers typically search for reliable information to inform future
research. New scholarly journal and article types dedicated to increasing accessibility of research data have emerged in
recent years and, in general, journals are developing stronger links with data repositories. There is a need for increased
collaboration between journals, data repositories, researchers, funders, and voluntary data sharing services to increase
the visibility and reliability of clinical research. Using the journal Scientific Data as a case study, we propose and show
examples of changes to the format and peer-review process for journal articles to more robustly link them to data
that are only available on request. We also propose additional features for data repositories to better accommodate
non-public clinical datasets, including Data Use Agreements (DUAs).Background
Open access to research data that can be understood
and reused by others is a means to further scientific
progress and publish more reliable and reproducible
research [1, 2]. However, clinical research data often
include information that could potentially identify indi-
viduals, meaning datasets must be anonymised prior to
being shared beyond the study for which the data were
originally collected. Although guidelines and processes
for anonymisation of clinical data exist [3, 4], publication
of freely available clinical datasets (such as [5]) remains
uncommon. As open access to clinical datasets is often
unfeasible, a more felicitous and pragmatic approach
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(http://creativecommons.org/publicdomain/zeSome clinical datasets may be made available on
request from authors of journal articles or through the
recent emergence of dedicated data request systems.
However, as large amounts of clinical research can go
unpublished [6, 7], and clinical trials unregistered [8],
the discoverability of many clinical datasets is subopti-
mal. In this paper, we use the term “non-public clinical
datasets” to mean datasets that have been generated
through experimental clinical research, such as clinical
trials, and which are not openly accessible, but are avail-
able on request. Clinical research involving surgical,
disease-specific or epidemiologic cohort databases, and
electronic health records, which can be continually up-
dated and held by an institution, should not be excluded
from data sharing but may require specific additional
guidance not covered in this paper.
In consultation with relevant stakeholders representing
pharmaceutical companies, research funders, researchersis article is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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of the journal Scientific Data propose guidelines for link-
ing peer-reviewed journal articles to non-public clinical
datasets. Throughout this paper, Scientific Data is used
as a case study of how these guidelines will work in
practice and we also propose how similar approaches
could be taken by other journals that consider manu-
scripts describing clinical or other data that cannot be
publicly available.
Data repositories are recognised as essential for enab-
ling reliable access to data underlying research in a num-
ber of life science disciplines. Their use is ingrained in
the practices of some research communities and in the
editorial policies of, for example, the Nature journals [2].
Common repositories for non-public clinical data are
less well established, however. We propose implementa-
tion of specific features in data repositories for the archival
of non-public clinical datasets, to enable appropriate
cross-linking of these datasets to scholarly journal articles.
Summary of recommendations
Clinical researchers and their sponsors
 Be prepared to share experimental data with editors,
peer reviewers and other researchers in accordance
with journal policies
 Apply the shortest possible embargoes on data
Repositories
 Develop mechanisms to host clinical research data,
including:
○ Provide stable identifiers for metadata records
about non-public dataset(s)
○ Implement Data Use Agreements (DUAs)
○ Implement a transparent system for requesting
access to data and reviewing requests to access
data
○ Allow access to data in a timely manner and
include a proportionate review of the scientific
rationale, without introducing unnecessary barriersClinical journal editors and publishers
 Check compliance with their journal’s data sharing
policies for every submission
 For manuscripts based on secondary access to trial
data (e.g. data the original trial sponsor has made
available for further research), check the research is
consistent with the DUA and purpose for which
data access was granted or ask authors to attest that
the submission is compliant with these conditions
 Increase the visibility of clinical datasets to peer
reviewers Build relationships with repositories for non-public
clinical datasets to support public archiving of
metadata and data from clinical research
 Introduce links to data, data sharing statements and
transparency statements in published articles
Data journal editors and publishers
 Develop data article formats (for example Scientific
Data’s Data Descriptor) to permanently link articles
to descriptions of non-public clinical datasets
All sponsors and funders of trials
 Build partnerships with and between data sharing
initiatives, trusted repositories, and peer-reviewed
journals committed to data sharing
 Apply the shortest possible embargoes on data and
ensure that data access is subject to a proportionate
review (e.g. of the scientific rationale and
qualifications of the research team), without
introducing unnecessary barriers
How do researchers currently access non-public clinical
data?
Data sharing between researchers has traditionally oc-
curred through direct contact between individuals and
research groups [9]. Many journals have policies that re-
quire authors to share data that support their results
with other researchers on request, but enforcement of
such policies varies between journals (for a summary of
journal policy types and approaches see [10]). Journal
policies that only require data to be “available on request”
without also mandating data availability statements have
been found to be less effective for ensuring data access for
future researchers [11–14]. However, even clinical journals
with strong and enforced policies on data access (such as
the BMJ and PLOS Medicine), data about identifiable
human subjects will usually not be in the public domain,
due to the need to protect research participants’ privacy.
Alongside changes in journal policies, initiatives from
other stakeholders (regulatory agencies, the pharmaceut-
ical industry and research groups) in clinical research
have begun to facilitate greater access to non-public
clinical datasets. This includes the European Medicines
Agency (EMA) which has committed to providing access
to individual patient data (IPD) in the future [15].
When surveyed about their data sharing attitudes and
behaviours, clinical researchers express concerns about in-
appropriate secondary analysis of their data and patient
privacy [16]. The Yale Open Data Access (YODA; http://
yoda.yale.edu/) project and Clinical Study Data Request
(CSDR; http://clinicalstudydatarequest.com) have since
2012 provided restricted access to non-public clinical
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January 2016, CSDR listed more than 2800 clinical studies
from 12 pharmaceutical companies, for which access to
data could be requested. Researchers are also able to
enquire about the availability of other non-listed stud-
ies. The project has been described as a success by
its independent data access review panel [17], and
179 research proposals (data requests) were submitted
between May 2013 and November 2015 (https://
www.clinicalstudydatarequest.com/Metrics.aspx). As of
March 2015 GlaxoSmithKline, one of the companies using
CSDR, had received 99 requests (approximately four re-
quests per month) to access data from the 1200 trials it
had listed. The YODA Project has compiled data from
more than 120 studies, representing two commercial data
providers, and has received 39 requests (http://yoda.
yale.edu/summary-data-inquiries-and-requests).
Connecting non-public clinical data with journals and
repositories
With increasing numbers of open access repositories for
research data for many scientific disciplines (http://
www.nature.com/sdata/data-policies/repositories; http://
www.re3data.org/), which provide persistent, citable
links to datasets and metadata records, it is relatively
easy to link journal articles to publicly accessible data. In
the area of clinical trials, the concept of allowing sec-
ondary researchers to access the data is relatively new
and so data are not yet widely shared. In addition, since
non-public clinical datasets often have no permanent
public record or identifier, links between these and the
peer-reviewed literature are far less robust than links be-
tween public datasets and the literature. This could be
addressed by developing both the data access policies of
journals and the relationships of journals with data re-
positories that can archive non-public datasets. Increas-
ing the visibility of such data could also be supported by
a new type of journal article focused on describing non-
public clinical datasets—particularly those that are
previously unpublished. These new articles could be an
adaptation of “data papers” that are already published in
data journals. Data journals are a relatively new type of
journal focused on data publication [18]. Below we
describe the benefits of this approach for researchers, as
opposed to simply posting information about non-public
datasets on a website or posting summary results of
clinical trials in trial registration databases.
Discoverability
YODA and CSDR provide public information about
clinical studies for which data are available on request.
Some of these studies may not be described in journal
articles, and for studies that are published, it may not be
clear in the published article that the underlying data areavailable. Moreover, when planning a new research pro-
ject or systematic review, medical researchers primarily rely
on bibliographic databases (such as PubMed/MEDLINE,
Scopus, Web of Science), individual journals and clinical
trial registries to find information rather than these web-
sites. Better links with journal articles, which are more vis-
ible due to indexing in bibliographic databases, might
increase the visibility and use of data on request services.
Scientific Data (http://www.nature.com/scientificdata)
from the Nature Publishing Group is one example of a
data journal (see [18] for others). It is an open access
journal for descriptions of scientifically valuable datasets,
where data articles (termed Data Descriptors) are linked
to their corresponding publicly available datasets. With
non-public datasets journal articles need to link to per-
sistent and citable metadata, a “stub” record or landing
page, for a clinical dataset that is available on request.
The landing page for a non-public clinical dataset should
contain sufficient metadata to facilitate an understanding
of what the dataset is, and importantly, the conditions
that must be met for access to the data (see below). Data
Descriptors (and other types of research-based article)
linked to the citeable landing page could then be written
by those who created the non-public clinical dataset, in-
creasing the discoverability of the dataset and providing
a means to obtain scholarly credit for generating and
sharing the data.
As well as increasing discoverability of content through
indexing in bibliographic databases open access journals,
in particular, can help ensure content is highly visible
through exposure to standard internet search engines
such as Google.
Quality and peer review
Peer review is central to publishing research in journals.
Publication of Data Descriptors at Scientific Data (and
some other data journals) involves formal peer review by
independently selected experts, of both the article
describing the dataset(s) and the dataset itself. The peer-
review process at Scientific Data focuses on (re)usability
and data integrity, rather than on the perceived import-
ance or impact of the data (http://www.nature.com/
sdata/for-referees). However, systematic peer review of
underlying data is not routine in traditional research
journals.
Data curation
Scientific Data’s publication process includes data cur-
ation by a dedicated Editor, in addition to peer reviewer
checks. This process includes the creation of standardised,
machine readable metadata for every Data Descriptor.
This is intended to facilitate data discoverability and reuse
by using controlled vocabulary terms to capture sample
and subject provenance, and outline the experimental
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should increase confidence in the delivered data formats,
adding further value to the offerings of data journals.
Use of subject-specific repositories, which tend to
use community-accepted data formats and standards,
and have standardised data curation processes, also
increases the likelihood that archived data can be
reused.
Permanence
A role of journals is to ensure the permanence and in-
tegrity of the scientific record, for example, by maintain-
ing persistent links between articles and datasets and
placing copies of content in redundant archives. Web
link decay or “link rot” is well documented, and even in
the peer-reviewed literature, an estimated 20 % of arti-
cles published in 2012 already suffer from broken web
links when regular websites or URLs are cited [19]. This
deterioration of referential integrity across correspond-
ing data sources presents obstacles to replicating or re-
analysing results underlying the scientific record.
Publishers’ use of persistent identifiers for journal articles,
Digital Object Identifiers (DOIs), helps ensure readers and
future researchers can access content as publishers com-
mit to keeping article links up-to-date using the DOI sys-
tem. DOIs are increasingly being created for datasets and
metadata records, via data repositories.
Links with data repositories
While the YODA Project and CSDR have succeeded in in-
creasing access to clinical research data, their websites, and
documents hosted therein are not citable and linkable in
the same way as journal articles, and other research objects
assigned DOIs. Furthermore, researchers and projects
funded by organisations such as Cancer Research UK,
Medical Research Council Clinical Trials Unit (MRC CTU)
[20] and the Wellcome Trust may have well-managed non-
public datasets available via local hosting, but these archives
are unlikely to meet preservation, discoverability and link-
ing standards of journals and publishers. Scientific Data, for
example, works with trusted repositories to publish its Data
Descriptors and supports data archiving policies and
activities across the Nature journals [2]. Scientific Data
has established criteria for assessing public research data
repositories (see below) and has so far approved more
than 80 repositories (http://www.nature.com/sdata/data-
policies/repositories; https://biosharing.org/collection/
ScientificData). Other publishers and journals also list
suggested or recommended repositories for authors
including BMJ Open, PLOS, and BioMed Central.
Negative, incomplete or inconclusive trial data
While a number of journals exist that explicitly encour-
age negative or inclusive trials to be published (such asTrials, Journal of Negative Results in Biomedicine), a
type of article designed to describe non-public clinical
trial data—regardless of whether discussion or analysis
of the data are available—might be further incentive for
researchers and their sponsors to share data.Alternative approaches to data sharing
While this paper proposes an important role for journals
and data journals in making non-public research data
more widely available, other approaches exist. We sum-
marise some of these and their advantages and disadvan-
tages in Table 1.
While these other models are not completely incon-
sistent with data publications, the involvement of jour-
nals and data journals in data sharing and publication
additionally provides independent data quality evalu-
ation, better preservation through dedicated independ-
ent repositories, and data access or request procedures
that are more transparent and less susceptible to bias.Additional considerations for journals and data
repositories
Data repositories that host non-public clinical datasets
which are linked to peer-reviewed articles need to pro-
vide the following additional services to those repositor-
ies hosting only publicly accessible data.Data use agreements
An essential component for the secondary use of non-
public clinical datasets is a data use agreement (DUA)
between the data generator or repository and the sec-
ondary researcher(s). The purposes of DUAs include re-
ducing risks to participants and other parties involved in
the study and to ensure the scientific value of secondary
analyses, which includes commitments to publishing
secondary analyses in peer-reviewed journals [21].
Template DUAs are provided by the YODA Project
and CSDR (https://www.clinicalstudydatarequest.com/
Documents/DATA-SHARING-AGREEMENT.pdf ). The
Multi-regional Clinical Trials Center at Harvard University
also provides a template DUA (http://mrctcenter.org/
resources/?project=framework-for-data-sharing).
Recommending wording for DUAs is beyond the
scope of these guidelines. However, the position of
Scientific Data is that DUAs describing datasets
intended for publication in journals dedicated to open
science should support wider use by independent quali-
fied researchers, including for competitive analysis, and
that the authors agree to relinquish intellectual prop-
erty claims stemming from the data. Mandatory re-
quirements for co-authorship for data creators should
be avoided.
Table 1 Advantages and disadvantages of alternative approaches to data sharing
Approach Description Advantages Disadvantages Link/example
The ‘Beacon’ model • A common web service allows
researchers to discover data
relevant to their research without
the data holder storing the data
outside the host institution
• Comparatively easy to implement All those of share-on-request
systems, including:
Being piloted by Global Alliance for




• Can improve discoverability of
clinical datasets which cannot be
openly shared
• Lack of data preservation
guarantees
• No independent governance of
data requests
• No common system for citing
datasets
The ‘Federation’ model • Separate, locally controlled data
resources share a common index
and data transfer protocols
• Improved data preservation over
the Beacon model
• Data preservation relies on
multiple partner nodes.
Global Alzheimer’s Association
Interactive Network (GAAIN) [40]
http://www.gaain.org/
• Easier for institutions and ethical
committees to accept because
data holder does not give up
control of the data to an
independent repository
• No independent governance of
data requests
• Terms for anonymous peer
review of data, if permitted,
would likely need to be
negotiated with each node
independently
• Linking with the literature
possible if stable data identifiers
are used across the whole
network
The ‘Iron-safe’ model • Data stored in a hardened,
centralised resource and analysis
conducted within the confines of
the system
• Appropriate for highly sensitive
data collected in the course of
clinical care
• Access barriers may be
prohibitive
Planned for 100,000 English
Genomes system (http://
www.genomicsengland.co.uk/the-
100000-genomes-project/data/)• Anonymous peer review of data
generally impossible• A centralised resource can, in
principle, provide an independent
system for vetting and providing
access, helping avoid the creep of
biasing access requirements like
co-authorship
• Difficult to link data with
literature in a robust manner, if
the index of the data resource is
also protected
Also, similar to the Clinical Study
Data Request (CSDR) model
• Data export from the system is
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Few repositories have processes for managing and approv-
ing requests to access non-public clinical datasets but we
identify some candidates and possible candidates (Table 2).
Controlled access approaches for IPD have been described
by Tudur Smith et al. [22]—which, for clinical trials, do
not always use data repositories—can include independent
advisory or data access committees. The role of a trusted
intermediary and characteristics of independent review
panels are highlighted by the IOM’s report [21] (chapter
5). The report recommends holders of clinical trial data
implement “operational strategies that include employing
data use agreements, designating an independent review
panel, including members of the lay public in governance,
and making access to clinical trial data transparent.”
Independent panels are costly to manage—employed
typically by large pharmaceutical companies or major
research funders—and there is no widely established
governance solution for all experimental clinical research
data.
Some concerns have been raised about the speed of data
release and usability of data from “voluntary data-sharing
portals” [23] such as YODA and CSDR, and, more
broadly, clinical trial units are understandably concerned
about costs of managing controlled access to data [24].
Landing pages
Repository metadata records (landing pages) for linking
journal articles to non-public clinical data will share many
characteristics with repository records for public datasets.
Good practice for data citation (citing of datasets in the
reference list/bibliography similar to citing papers) is for
links to datasets to resolve to landing pages rather than
the raw data files. Standards are emerging for the informa-
tion that is essential and desirable to be included in
landing pages [25]. These standards consist of a dataset
description comprising a dataset identifier, title and brief
description, creator, publisher, and publication year. Land-
ing pages should also include persistence/permanence
information and licensing information for the data. We
recommend that landing pages for non-public clinical
datasets also include information detailing the access con-
trols pertinent to the data. Examples of landing pages can
be found at the UK Data Archive (e.g. http://dx.doi.org/
10.5255/UKDA-SN-7612-2) and the European Genome-
phenome Archive (e.g. https://www.ebi.ac.uk/ega/datasets/
EGAD00000000001) and in Table 2. For clinical trials,
where prospective trial registration is established as ethical
research practice, we recommend unique trial identifiers
be included on landing pages.
Landing pages for non-public datasets in trusted
repositories (Table 2) can facilitate robust citation and
linking of papers reporting reanalysis of data obtained
on request. Papers reporting reanalysis of clinical dataaccessed via data request portals, including from YODA
[26] and Project Data Sphere [27] have begun to be
published, but can lack robust—citable—links to data
sources. A reanalysis of shared clinical data should ideally
cite, in the reference list, the paper reporting the primary
analysis of the data, the landing page(s) of the dataset(s)
themselves (where the data have persistent links, such as
DOIs) and, if applicable any data papers describing the
datasets. This helps provide credit and acknowledgement
to all those involved in data acquisition, sharing and ana-
lysis. Data repositories are also increasingly able to add
links to citing articles as they are published.
Additional repository assessment criteria
Taking the above issues into consideration, we propose
additional criteria by which journals and publishers can
assess repositories for hosting of non-public clinical
datasets:
Trusted repositories for non-public datasets must:
 Provide stable identifiers for metadata records about
non-public dataset(s)
 Allow access to data with the minimum of
restrictions needed to ensure protection of privacy
and appropriateness of secondary analyses, codified
in Data Use Agreements (DUAs)
 Allow access to data in a timely manner
 Provide support for users of data
Trusted repositories for non-public datasets should,
ideally:
 Be independent of the study sponsors and principal
investigators
 Have a transparent and persistent system for
requesting access to data and reviewing requests to
access data
 Provide relevant data analysis software environments
where data are not permitted to be downloaded
locally
 Provide public access to the metadata of archived
data for third party search and discovery
functionalities
These criteria are in addition to the current repository
selection criteria of Scientific Data which require trusted
repositories:
 Be broadly supported and recognised within their
scientific community
 Ensure long-term persistence and preservation of
datasets in their published form
 Implement relevant, community-endorsed reporting
requirements
Table 2 Data repositories that meet or potentially could meet the proposed requirements (in this article) for hosting non-public clinical trial data
Repository name Repository URL Type of data hosted Access controls Example of non-public clinical dataset
UK Data Service—ReShare http://reshare.ukdataservice.ac.uk All Requires account to request access
to specific dataset
https://dx.doi.org/10.5255/UKDA-SN-851861









database of Genotypes and
Phenotypes (dbGaP)
http://www.ncbi.nlm.nih.gov/gap Human genotype and phenotype
data




Harvard Dataverse http://dataverse.harvard.edu All Specific to each study, some data are
open
http://dx.doi.org/10.7910/DVN/25833




National Database for Clinical Trials
related to Mental Illness (NDCT)
http://ndct.nimh.nih.gov NIH funded data on any aspect of
human mental health [includes
National Database for Autism
Research (NDAR) and Research
Domain Criteria Database (RDoCdb)]








Drug addiction and HIV research
data
Requires account to request access
to specific dataset
http://doi.org/10.3886/ICPSR33581
Cancer Imaging Archive http://www.cancerimagingarchive.net/ Anatomical imaging of human
cancer
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 Allow public access to data without unnecessary
restrictions
Since this working group was formed, at least one
other group (Burton et al.) has proposed criteria for
“data safe havens” in healthcare [28].
Repositories that could or may meet the current and
additional requirements
Specialist trial data systems such as CSDR (and YODA)
have indicated a willingness to listen to feedback from re-
searchers and may evolve as data sharing progresses. As
well as the potential for these repositories to develop to
meet certain criteria, there are number of other general and
specialist repositories that could or may meet the above cri-
teria (Table 2), at least for specific types of clinical research.
There are also clinical data systems and “federations”
associated with specific projects and some have played
roles in disseminating data in specific communities. The
ADNI portal is one such example (http://neuroinformatics.
harvard.edu/gsp/loni). The group responsible for this por-
tal have published a peer-reviewed article [29] describing
and linking to non-public data in this resource.
Another Data Descriptor published at Scientific Data de-
scribes a non-public clinical dataset—of neuroimaging data
from brain tumour patients—hosted at the UK Data
Archive [30]. The Synapse repository has, also, enabled se-
cure access to patient self-reported clinical observation
data collected through smartphone apps—that have subse-
quently been described in and linked to peer-reviewed
publications [31]. Scientific Data has developed bespoke
workflows with Harvard Dataverse, UK Data Archive and
Synpase to facilitate anonymous peer review of confidential
datasets. Collaboration with the European Genome-
phenome Archive (EGA) has also facilitated journal coordi-
nated peer review of non-public human genome data [32].
Additional manuscript sections required
The format of published articles—data papers and trad-
itional research articles—needs to be developed to ac-
commodate links to non-public datasets.
Articles should include information about why the
data are not publicly available (i.e. because they contain
personally identifiable information) and describe the
restrictions on accessing the dataset. They should also
state if the data are subject to a DUA and where the
DUA can be found—ideally, this should be hosted per-
manently with the landing page of the non-public data-
set. In Scientific Data, the Usage Notes section would be
appropriate for this information. Persistent links to land-
ing pages should also be cited, in the same way public
datasets are cited. Other journals, such as PLOS ONE,
Genome Biology, Palgrave Communications, GigaScienceand Royal Society Open Science are now routinely
including dedicated article sections to describe and link
to datasets supporting published articles—these could be
adapted to meet these requirements.
Where Data Descriptors, and other articles, link to
non-public clinical datasets, we recommend authors
include in their articles a transparency declaration guar-
anteeing that their description of the dataset is an honest
and accurate account. Transparency statements for regu-
lar journal articles, for other aspects of research integ-
rity, have been implemented by the BMJ [33].
See Fig. 1 for an overview of the standard editorial
workflow of Scientific Data and Fig. 2 for the proposed
modified workflow to accommodate Data Descriptors of
non-public clinical datasets.
Research participant consent
Part of a journal’s role is to enforce relevant ethical ex-
pectations regarding consent. An important consider-
ation is whether participants gave appropriate consent
for data to be made available to secondary researchers in
the future (if data are not fully anonymised [3]). Where
informed consent for data sharing was obtained, consent
should include scholarly publications (peer-reviewed ar-
ticles) that describe or link to datasets.
What data should be available to secondary researchers?
Different types of experiments produce different types of
information in a variety of formats, leading to different
minimum requirements for secondary researchers seek-
ing to replicate or understand results. In general, repro-
ducible medical research requires access to data, code,
and study protocols [34]. CSDR has, furthermore,
defined data and document types for the studies it lists, al-
though all items are not always available for each study:
i. Raw dataset
ii. Blank case report forms
iii. Annotations of blank case report forms
iv. Dataset specifications
v. Protocol (all versions)
vi. Analysis-ready dataset
vii. Reporting and analysis plan
viii. Clinical study report
While the scope of these guidelines potentially goes be-
yond clinical trials—including molecular data types—this
list defined by CSDR is a reasonable guide. The IOM has
also described the clinical research data types that are
needed for reanalysis, which differs slightly from the CSDR
list (Chapter 5, p. 112) [21]. Standards for reusability for
historic, non-public clinical datasets might need to be less
stringent if data are only available in file formats that
might not be optimised for reuse.
Fig. 1 Overview of standard Scientific Data editorial workflow for non-confidential datasets. With submission of a Data Descriptor, authors provide a
secure link to dataset(s) stored in an external repository. Editors and referees are granted access to the data, in a manner that does reveal their
identities to the authors. Upon publication, both the article and the datasets are made freely accessible online under appropriate terms or licences
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The consensus of regulators, industry sponsors and fun-
ders of clinical trials is for data access to be granted to
suitably qualified researchers with a legitimate reanalysis
proposal. A requirement of CSDR’s procedures is that aFig. 2 Overview of an example editorial workflow accommodating peer re
describing a clinical restricted-access dataset, authors provide with their su
of the DUA. A process is then agreed between the journal and the authors
peer review. Upon publication, the article is made openly available, and the
Users may request access to the data according to the process and termsresearcher with a degree in statistics or a related discipline
should be part of the research team. The Independent
Review Panel for CSDR had, as of February 2015,
approved 71 requests and rejected or advised to resubmit
4 requests. The YODA Project’s approval committeeview and publication of clinical Data Descriptors. For Data Descriptors
bmission a description of where the dataset(s) are hosted and a copy
, by which referees and editors may request access to the data during
host data repository releases a landing page for the clinical dataset(s).
outlined in the Data Descriptor and associated DUA
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tor, Key Personnel, and the project Research Proposal,
including a scientific abstract and research methods”
when reviewing data access requests [35].
Journal polices generally require data supporting sub-
mitted works must be accessible to peer reviewers and
editors, and study sponsors should already be used to
providing access to data supporting manuscripts submit-
ted to major medical journals. These repository criteria
and guidelines could make these processes more effi-
cient if applied to clinical research journals. To publish
Data Descriptors in Scientific Data, peer reviewers and
editors must be given controlled access to supporting
data for every article. The majority of journals operate
single or double blind peer review, which means some
reviewers or journals might require their anonymity to
be maintained (public data repositories often support
anonymous peer review, although there is increasing
adoption of open peer review).
Peer review of non-public clinical datasets
Journals that implement these guidelines will be able to
make non-public clinical datasets more visible to peer re-
viewers, potentially, as well as editors. Scientific Data is
reviewing its peer review guidelines (http://www.nature.
com/sdata/for-referees#writing-review) as it considers the
first articles describing non-public datasets, but many
journals have their own guidelines and processes for their
peer reviewers. In general, however, peer review of articles
describing and linking to non-public clinical datasets
should include but not be limited to:
 Whether the access controls on the data are
warranted and if enough information is provided on
how to request access to the data
 Whether the data are sufficiently well described to
enable independent researchers to assess the reuse
value of the dataset (to help ensure data requested
are reused)
When to provide secondary access to data
The IOM has recommended embargoes of up to
18 months from study completion before clinical trialists
are required to share data, although this has been criticised
for being too long [36]. The International Committee of
Medical Journal Editors (ICMJE) in 2016 proposed a draft
policy for its member journals requiring sharing of anon-
ymised IPD within 6 months of publication [37]. In a
major epidemic, a long embargo on data access and reuse
could be to the detriment of fighting disease. But a reason-
able period for analysis—a right of first use—is acknowl-
edged in most research communities. Any embargo on
non-public clinical dataset(s) described in and linked to a
journal article would have to have expired to comply withthe recommendations in this article. In general we advo-
cate no, or short, embargoes on data release wherever
feasible.
Conclusion
In consultation with a working group (see Acknowledgements),
Scientific Data is developing its editorial and peer-review
processes and relationships with repositories to support
publication of Data Descriptors for non-public clinical
datasets as we receive relevant submissions. Other jour-
nals—data journals and traditional journals—may wish to
consider these repository, linking and editorial policy pro-
posals. Some members of our working group are also
helping to identify interested research teams and relevant
datasets that could be part of a publication pilot. Indeed,
we need real data with which to develop more robust links
between non-public datasets and journal articles. We
strongly encourage others to contact the editors
(scientificdata@nature.com), to discuss proposals.
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